Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCL8 | P10145 | 9/20 | 0.57 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.56 |
| ▸ | DPP3 | Q9NY33 | 5/20 | 0.56 |
| ▸ | REN | P00797 | 1/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30953538 | 0.91 | DPP3 (0.62) | C5AR1DPP3RENSLC6A2OPRM1 | |
| SCHEMBL19787869 | 0.87 | DPP3 (0.69) | C5AR1DPP3RENSLC6A2OPRM1 | |
| SCHEMBL30949447 | 0.87 | CXCL8 (0.63) | CXCL8SLC6A2 | |
| SCHEMBL29733647 | 0.87 | C5AR1 (0.63) | CXCL8C5AR1 | |
| SCHEMBL30512506 | 0.86 | CXCL8 (0.61) | CXCL8DPP3OPRM1 | |
| SCHEMBL29575470 | 0.86 | DPP3 (0.61) | C5AR1DPP3SLC6A2OPRM1OPRD1 | |
| SCHEMBL31402672 | 0.86 | KISS1R (0.63) | DPP3RENSLC6A2OPRM1 | |
| SCHEMBL30311066 | 0.86 | CXCL8 (0.63) | CXCL8DPP3OPRM1 | |
| SCHEMBL31332301 | 0.85 | CXCL8 (0.59) | CXCL8DPP3 | |
| SCHEMBL31247508 | 0.85 | CXCL8 (0.55) | CXCL8DPP3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230058316-A1 | PEGYLATED IGE-DEPENDENT HISTAMINE-RELEASING FACTOR (HRF)-BINDING PEPTIDE AND USE THEREOF | EWHA UNIVERSITY - INDUSTRY COLLABORATION FOUNDATION (KR) | 2023-02-23 | — | — | US | disclosed |
| WO-2015102418-A2 | PEPTIDOMIMETIC COMPOUND AND PHARMACEUTICAL COMPOSITION FOR TREATING ALLERGIC DISORDERS INCLUDING SAME | 이화여자대학교 산학협력단 | 2015-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230058316-A1 | PEGYLATED IGE-DEPENDENT HISTAMINE-RELEASING FACTOR (HRF)-BINDING PEPTIDE AND USE THEREOF | HDGF, HRH3, HRH4 | CXCL8 548/4885C5AR1 40/4885DPP3 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.